Description: Provide users with a demonstration of the 2012 IDEC Claim Incidence and Termination Rate Tables and adjustments to these tables to reflect experience of key segments of the business. Compares active life and disabled life reserves based on the Base Tables and CIDA.

Description: 2001 individual life and annuity expense study summary report updated 10-01-03.

Description: Appendices A, B, and C for the Factors That Affect Retirement Mortality FARM Phase II. These appendices provide the format for data submission by contributors to the Mortality and Turnover Study, the SOA & LIMRA Experience Studies, and the Structured Settlement Study.

Description: The Society of Actuaries and two of its special interest sections, the Pension Section and the Health Section, set about creating a pension plan turnover table for use by actuaries to assist in calculating benefit costs for pension and retiree medical plans. This is the final report about that project.

Description: The Committee on Life Insurance Company Expenses is currently seeking life insurance company data submissions to the 2008 Individual Life and Annuity Expense Study. This is the data submission form. Please see the SOA website experience studies for the completed report.

Description: Unique Data Analysis Techniques to help plans find that 1% edge in opportunity and value. The discussion will vary from a conversation on members who are at high catastrophic risk to provider networks and referral patterns. The goal of the session will be to help show ways plans can create savings through outside-the-box techniques.

Description: A comprehensive primer on long-term care wellness programs, their design, implementation, challenges, metrics for success, and emerging industry practices.

Description: Attend this webcast to learn more on how to navigate managing ESG principles in the new normal of a post-COVID world. Enhance your ESG insights in a post-pandemic landscape.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Given the rise in interest rates during 2022, explore the implications of increasing rates on FA and FIA business by looking at industry experience for FA and FIA products for 2022 compared to earlier years. Additionally, come walk through partial withdrawals, GLWB utilization, mortality and what to expect as interest rate volatility continues. You'll also discover how direct writers and reinsurers are handing the in-force management aspects of these products in the uncertain and volatile economic periods. Key learning outcomes include: - Understand the impact of rising rates on dynamic lapse for FA and FIA products - Explanation ofin-force management actions that are being taken in the current interest rate environment - Be informed of current trends in GLWB utilization